Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | melanoma |
| ICD-0-3 | NA |
| Methods | qPCR, RNAi, Western blot, Cell migration assay etc. |
| Sample | cell line (OM431) |
| Expression Pattern | up-regulated |
| Function Description | Real-time polymerase chain reaction (PCR) results indicated that ANRIL expression is upregulated in the two melanoma cell lines. In cell culture, this treatment significantly reduced the tumor metastatic capacity and tumor formation compared with absence of treatment. In animals harboring tumor xenografts, this therapeutic approach significantly inhibited tumor growth and reduced the tumor weight. |
| Pubmed ID | 27461581 |
| Year | 2016 |
| Title | ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma. |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for melanoma | OMIM COSMIC |